Jubilant Pharmova Files SEBI Certificate for Q2 FY27
Jubilant Pharmova Limited submitted a SEBI Regulation 74(5) certificate for the quarter ended September 30, 2026. The certificate from Alankit Assignments Limited confirms dematerialization of physical shares and updates to the company's records.
This is a standard compliance filing related to share dematerialization and does not have a direct impact on the company's operations, financial performance, or stock price.
The announcement is a routine regulatory filing and does not contain any material financial or business updates that would indicate a positive or negative sentiment.
Jubilant Pharmova Limited has submitted a confirmation certificate for the quarter ended September 30, 2026, as per Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This certificate was received from Alankit Assignments Limited, the company's Registrar and Share Transfer Agent.
The certificate confirms that the securities held in physical form and received for dematerialization have been processed. Specifically, it states that the securities are listed on the stock exchanges, and the physical certificates have been duly verified, mutilated, and cancelled. The name of the depository has been substituted as the registered owner in the company's records.
This submission is a routine compliance filing with the stock exchanges, including BSE Limited and the National Stock Exchange of India Limited.
What to do with a filing like this
Jubilant Pharmova Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jubilant Pharmova Limited. Read the original for the full detail.